Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction

Pulmonary Circulation

Volumn 7, Issue 2, 2017, Pages 409-420

  Bourji, Khalil I ^a,b   Kelemen, Benjamin W ^a   Mathai, Stephen C ^a   Damico, Rachel L ^a   Kolb, Todd M ^a   Mercurio, Valentina ^a   Cozzi, Franco ^b   Tedford, Ryan J ^a   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

HFpEF; Left heart disease; Pulmonary hypertension; Scleroderma

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; SODIUM; URIC ACID;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEART ATRIUM ENLARGEMENT; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART RIGHT VENTRICLE PRESSURE; HEMODYNAMICS; HUMAN; LUNG PRESSURE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SCLERODERMA; SIX MINUTE WALK TEST; SURVIVAL; SURVIVAL TIME; SYSTEMIC SCLEROSIS; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 85021254971     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1177/2045893217700438     Document Type: Article

References (43)

1. Steen VD and Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66(7): 940–944.
2. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62(11): 1088–1093.
3. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52(12): 3792–3800.
4. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46(4): 903–975.
5. de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67(1): 31–36.
6. Fox BD, Shimony A, Langleben D, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013; 42(4): 1083–1091.
7. Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37(11): 2290–2298.
8. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and sclerodermarelated pulmonary hypertension. Arthritis Rheum 2006; 54(9): 3043–3050.
9. Clements PJ, Tan M, McLaughlin VV, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012; 71(2): 249–252.
10. Tedford RJ, Hassoun PM, Mathai SC, et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012; 125(2): 289–297.
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23(5): 581–590.
12. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma- related pulmonary hypertension. Eur Respir J 2010; 35(1): 95–104.
13. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177(11): 1248–1254.
14. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66(11): 1467–1472.
15. Vanderpool RR, Pinsky MR, Naeije R, et al. RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. Heart 2015; 101(1): 37–43.
16. Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in ‘‘outof- proportion’’ pulmonary hypertension. Chest 2013; 143(3): 758–766.
17. Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014; 146(6): 1494–1504.
18. Al-Naamani N, Preston IR, Paulus JK, et al. Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail 2015; 3(6): 467–474.
19. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182(2): 252–260.
20. Schoenfeld DA. Sample-size formula for the proportionalhazards regression model. Biometrics 1983; 39(2): 499–503.
21. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995; 14(15): 1707–1723.
22. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community- based study. J Am Coll Cardiol 2009; 53(13): 1119–1126.
23. Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014; 130(25): 2310–2320.
24. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69(1): 218–221.
25. Meune C, Avouac J, Wahbi K, et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58(6): 1803–1809.
26. Schreiber BE, Valerio CJ, Keir GJ, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011; 63(11): 3531–3539.
27. Robbins IM, Newman JH, Johnson RF, et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009; 136(1): 31–36.
28. Dote K, Miyasaka Y, Tsujimoto S, et al. Obesity as an independent risk for left ventricular diastolic dysfunction in 692 Japanese patients. Obes Res Clin Pract 2012; 6(3): e175–262.
29. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72(12): 1940–1946.
30. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol 2003; 42(7): 1206–1207.
31. Takemoto Y, Barnes ME, Seward JB, et al. Usefulness of left atrial volume in predicting first congestive heart failure in patients>or = 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol 2005; 96(6): 832–836.
32. Patel DA, Lavie CJ, Milani RV, et al. Left atrial volume index predictive of mortality independent of left ventricular geometry in a large clinical cohort with preserved ejection fraction. Mayo Clin Proc 2011; 86(8): 730–737.
33. Thenappan T, Shah SJ, Gomberg-Maitland M, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011; 4(3): 257–265.
34. Abu-Shakra M and Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995; 22(11): 2100–2102.
35. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123(2): 344–350.
36. Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosisrelated pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63(8): 2456–2464.
37. Faludi R, Kolto G, Bartos B, et al. Five-year follow-up of left ventricular diastolic function in systemic sclerosis patients: determinants of mortality and disease progression. Semin Arthritis Rheum 2014; 44(2): 220–227.
38. Tedford RJ, Beaty CA, Mathai SC, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant 2014; 33(3): 289–297.
39. Tampakakis E, Leary PJ, Selby VN, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 2015; 3(1): 9–16.
40. Assad TR, Brittain EL, Wells QS, et al. Hemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertension. Pulm Circ 2016; 6(3): 313–321.
41. Tedford RJ, Mudd JO, Girgis RE, et al. Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6(5): 953–963.
42. Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37(12): 942–954.
43. Robbins IM, Hemnes AR, Pugh ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014; 7(1): 116–122.